Abstract:
This invention is directed to the crystalline potassium salt of a lipoxin A4 analog of Formula (I): processes for preparing the crystalline potassium salts, methods for using them to treat disease-states characterized by inflammation, and pharmaceutical compositions comprising such crystalline potassium salts.
Abstract:
This invention is directed to the crystalline potassium salt of a lipoxin A4 analog of Formula (I): processes for preparing the crystalline potassium salts, methods for using them to treat disease-states characterized by inflammation, and pharmaceutical compositions comprising such crystalline potassium salts.
Abstract:
This invention is directed to the crystalline potassium salt of a lipoxin A4 analog of Formula (I): processes for preparing the crystalline potassium salts, methods for using them to treat disease-states characterized by inflammation, and pharmaceutical compositions comprising such crystalline potassium salts.
Abstract:
A homogenous catalyst is prepared by reacting a ruthenium or molybdenum carbene catalyst of formula (I): in a non-reactive organic solvent or solvent mixture with a bicyclic olefin of formula (II): wherein X is O, NR1, C(R1)2, S, POR6, or PR6; R1 and R2 independently of each other, are H, (C1-C8)-alkyl, (C2-C8)-alkenyl, (C2-C8)-alkynyl, (C6-C18)-aryl, (C7-C19)-aralkyl, (C3-C18)-heteroaryl, (C4-C19)-heteroaralkyl, (C3-C8)-cycloalkyl, (C3-C8)-cycloalkenyl, (C6-C18)-aryl-(C1-C8)-alkyl, (C3-C18)-heteroaryl-(C1-C8)-alkyl, (C3-C8) -cycloalkyl-(C1-C8)-alkyl, or (C1-C8)-alkyl-(C3-C8)-cycloalkyl, or form together an ═O group; R3 and R4, independently of each other are OR1, SR1, NR12, OR7, SR7, or NR1R7 provided that at least one residue R3 or R4 bears a group R7, R6 is R1, provided that R6 is not H; R7 is a catalytically active group, and optionally with a further olefinic compound (III).
Abstract:
The present invention relates to a new process for preparing estrogen-antagonistic 11β-fluoro-17α-alkylestra-1,3,5(10)-triene-3,17-diols of the general formula I having a 7α-(ξ-alkylamino-ω-perfluoroalkyl)alkyl side chain and to α-alkyl(amino)-ω-perfluoro(alkyl)alkanes of the general formula II, to processes for their preparation and to the intermediates required for this purpose.
Abstract:
This invention is directed to the crystalline potassium salt of a lipoxin A4 analog of Formula (I): processes for preparing the crystalline potassium salts, methods for using them to treat disease-states characterized by inflammation, and pharmaceutical compositions comprising such crystalline potassium salts.
Abstract translation:本发明涉及式(I)的脂氧素A 4 H 4类似物的结晶钾盐:制备结晶钾盐的方法,其用于治疗以炎症为特征的疾病状态的方法,以及 包含这种结晶钾盐的药物组合物。